Skip to content
CPHK

CPHK

Toggle menu
  • Home
  • This is Us
    • History
    • Goals
    • Core Team
    • Leadership
    • Collaborative Hubs
  • Our Universe
    • Public Health Interests
    • Footprint
    • Research Collaborators
    • Areas of Work
    • Focus
  • Describing Us
    • Proficiencies
    • Approach
    • Projects Undertaken
      • India
      • Tanzania
    • Innovation & Impact
    • Supporting WHO
  • Universal Family
    • Partnerships
    • Funders & Donors
  • Resource Center
    • Publications
    • Workshops
    • Presentations
    • Top Citation
    • Gallery
    • Advertised Positions
  • Global Health
    • Lancet
    • Sci
    • NEJM
    • Tanzania
    • India
    • Global health update
  • Contact
February 25, 2022Uncategorized

Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis

Post Content

February 25, 2022Uncategorized

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial

Post Content

February 25, 2022Uncategorized

A woman pregnant with twins has fever, haemolysis, and thrombocytopenia caused by babesiosis: could be confused with HELLP syndrome

Post Content

February 25, 2022Uncategorized

Our commitment to help accelerate progress against cancer

Post Content

February 23, 2022Uncategorized

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

To our knowledge, this study provides the first comprehensive assessment of the global burden of AMR, as well as an evaluation of […]

February 22, 2022Uncategorized

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

COVID-19 vaccine efficacy or effectiveness against severe disease remained high, although it did decrease somewhat by 6 months after full vaccination. By […]

February 21, 2022Uncategorized

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

All study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. […]

February 21, 2022Uncategorized

Offline: A lie at the heart of public health

Post Content

February 21, 2022Uncategorized

Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial

Post Content

February 21, 2022Uncategorized

COVID-19 will continue but the end of the pandemic is near

The world is experiencing a huge wave of infection with the omicron variant of SARS-CoV-2. Estimates based on Institute for Health Metrics […]

Posts pagination

< 1 2 3 … 6 >

Recent Posts

  • [Action required] Your RSS.app Trial has Expired.
  • Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis
  • Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial
  • Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis
  • The global COVID-19 treatment divide

Recent Comments

    Archives

    • March 2022
    • February 2022
    • October 2019

    Categories

    • Uncategorized
    • work

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Recent News

    • [Action required] Your RSS.app Trial has Expired. March 13, 2022
    • Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis February 26, 2022
    • Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial February 26, 2022

    Categories

    • Uncategorized
    • work

    Archives

    • March 2022
    • February 2022
    • October 2019

    Popular Tags

    CREATIVE IDEAS MUSIC PHOTOGRAPHY UNIQUE WORDPRESS TEMPLATE
    • Home
    • This is Us
    • Our Universe
    • Describing Us
    • Universal Family
    • Resource Center
    • Global Health
    • Contact
    © 2025 CPHK. Proudly powered by Sydney